Circadian Technologies Limited  

(Public, ASX:CIR)   Watch this stock  
Find more results for Mike Fisher´┐Ż
+0.010 (3.13%)
Delayed:   10:12AM GMT+11
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.33 - 0.33
52 week 0.14 - 0.33
Open 0.33
Vol / Avg. 27,500.00/42,595.00
Mkt cap 45.69M
P/E     -
Div/yield     -
EPS -0.06
Shares 148.09M
Beta     -
Inst. own     -
Feb 15, 2016
Interim 2016 Circadian Technologies Ltd Earnings Release (Estimated) Add to calendar
Nov 30, 2015
Circadian Technologies Ltd Annual Shareholders Meeting - 11:00AM GMT+11 - Add to calendar
Nov 18, 2015
Circadian Technologies Ltd Annual Shareholders Meeting (Estimated)

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -415.91% -575.18%
Operating margin -695.68% -899.40%
EBITD margin - -895.30%
Return on average assets -19.08% -29.61%
Return on average equity -21.66% -34.90%
Employees 5 -
CDP Score - -


Suite 0403 Level 4, 650 Chapel Street, South Yarra
+61-3-98260399 (Phone)
+61-3-98240083 (Fax)

Website links


Circadian Technologies Limited is engaged in developing and commercializing therapies for cancer and eye diseases. The Company focuses on developing activities, which covers targets, including vascular endothelial growth factors (VEGF-C, VEGF-D and VEGF receptor-3). It develops therapies for the treatment of diseases associated with blood and lymphatic vessel growth, such as angiogenesis, lymphangiogenesis and vascular leakage. Its lead molecule, OPT-302, is in development stage and is a soluble form of VEGFR-3. Its OPT-302 blocks blood and lymphatic vessel growth, and inhibits vascular leakage. Its therapeutic product pipeline also includes VGX-100, a neutralizing monoclonal antibody for VEGF-C, and IMC-3C5, a neutralizing monoclonal antibody for VEGFR-3. The Company, through its subsidiary, Opthea Pty Ltd, is developing OPT-302 for the treatment of wet age-related macular degeneration (wet AMD). Its subsidiaries also include Ceres Oncology Pty Ltd and Vegenics Pty Ltd.

Officers and directors

Megan Baldwin Ph.D. Chief Executive Officer, Managing Director, Director
Michael Tonroe Chief Financial Officer, Company Secretary
Richard Chadwick Ph.D. Head - Intellectual Property
Mike Gerometta Head of CMC Development
Ian Leitch Director - Clinical Research
Dominique Gayle Fisher Non-Executive Chairman of the Board
Russell John Howard Ph.D. Non-Executive Director
Tina Renna McMeckan Non-Executive Director